SGHT SIGHT SCIENCES INC

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022, at 2:30pm ET.

Interested parties can access a live webcast of the presentation directly by following this . An archived webcast of the presentation will be available on the “Investors” section of the Sight Sciences website at following the event.

Those parties interested in registering for the Inaugural Gilmartin Group Emerging Growth Company Showcase may do so by following this .

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit .

OMNI® and TearCare® are registered trademarks of Sight Sciences.

SION™ is a trademark of Sight Sciences.

© 2022 Sight Sciences. All rights reserved.

Investor contact:

Philip Taylor

Gilmartin Group

415.937.5406



EN
25/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SIGHT SCIENCES INC

 PRESS RELEASE

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology For...

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and arch...

 PRESS RELEASE

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffi...

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights G...

 PRESS RELEASE

Sight Sciences to Report First Quarter 2025 Financial Results on May 8...

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company’s management will discuss the results during a conference call begin...

 PRESS RELEASE

Sight Sciences Announces the Release of its Sustainability Report

Sight Sciences Announces the Release of its Sustainability Report The Sustainability Report provides data for 2022 through 2024 on the Company’s environmental, social, and governance initiatives MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company’s sustainability activities, performance and results from the ...

 PRESS RELEASE

Sight Sciences Appoints Gary Burbach to its Board of Directors

Sight Sciences Appoints Gary Burbach to its Board of Directors MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company’s Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. “We are very excited to add Ga...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch